Skip to main content
Top
Published in: Journal of General Internal Medicine 4/2023

23-09-2022 | Anticoagulant | Original Research

Association of Neighborhood Disadvantage and Anticoagulation for Patients with Atrial Fibrillation in the Veterans Health Administration: the REACH-AF Study

Authors: Annie McDermott, BS, Nadejda Kim, MA, Leslie R.M. Hausmann, PhD, MS, Jared W. Magnani, MD, MSc, Chester B. Good, MD, MPH, Terrence M.A. Litam, MHA, Maria K. Mor, PhD, Toluwa D. Omole, BS, Walid F. Gellad, MD, MPH, Michael J. Fine, MD, MSc, Utibe R. Essien, MD, MPH

Published in: Journal of General Internal Medicine | Issue 4/2023

Login to get access

Abstract

Background

Atrial fibrillation (AF) is a common arrhythmia, the management of which includes anticoagulation for stroke prevention. Although disparities in anticoagulant prescribing have been well documented for individual socioeconomic factors, less is known about the association of neighborhood-level disadvantage and anticoagulation for AF.

Objective

To assess the association between neighborhood disadvantage and anticoagulant initiation for patients with incident AF.

Design

Retrospective cohort study.

Participants

A cohort of patients enrolled in the Veterans Health Administration (VA) with incident AF from January 2014 through December 2020 from the Race, Ethnicity, and Anticoagulant CHoice in Atrial Fibrillation (REACH-AF) Study.

Main Measures

The primary exposure was neighborhood disadvantage quantified using area deprivation index (ADI), classified by quintiles (Q). The outcomes were initiation of any anticoagulant therapy (warfarin or direct oral anticoagulant, DOAC) within 90 days of AF diagnosis and DOAC use among initiators. We used mixed effects logistic regression to assess the association between ADI and anticoagulant therapy, incorporating a fixed effect for treatment site and baseline patient, provider, and facility covariates.

Key Results

Among 161,089 patients, 105,489 (65.5%) initiated any anticoagulant therapy, and 78,903 (74.8%) used DOACs. Any anticoagulant therapy increased 3.2 percentage points (63.0% to 66.2%; p<.001) from Q1 to Q5, whereas DOAC use decreased 8.2 percentage points (79.4% to 71.2%; p<.0001) across quintiles. The adjusted odd ratios of any anticoagulant therapy were non-significantly different for Q2–Q5 than Q1. The adjusted odds of DOAC use decreased progressively from 0.89 (95% CI, 0.84–0.94) in Q2 to 0.77 (95% CI, 0.73–0.83) in Q5 compared to Q1 (p<.0001).

Conclusions

Among Veterans with incident AF, we observed similar initiation of any anticoagulant, though neighborhood deprivation was associated with decreased DOAC use among anticoagulant initiators. Future interventions to improve pharmacoequity in anticoagulant prescribing for AF should consider the role of neighborhood-level determinants of health inequities.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-847.PubMedCrossRef Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-847.PubMedCrossRef
2.
go back to reference Essien UR, Kornej J, Johnson AE, Schulson LB, Benjamin EJ, Magnani JW. Social determinants of atrial fibrillation. Nat Rev Cardiol. 2021;18(11):763-773.PubMedPubMedCentralCrossRef Essien UR, Kornej J, Johnson AE, Schulson LB, Benjamin EJ, Magnani JW. Social determinants of atrial fibrillation. Nat Rev Cardiol. 2021;18(11):763-773.PubMedPubMedCentralCrossRef
3.
go back to reference Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update: a report From the American Heart Association. Circulation. 2021;143(8):e254-e743.PubMedCrossRef Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update: a report From the American Heart Association. Circulation. 2021;143(8):e254-e743.PubMedCrossRef
4.
go back to reference Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8a):2n-9n.PubMedCrossRef Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8a):2n-9n.PubMedCrossRef
5.
go back to reference Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952.PubMedCrossRef Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952.PubMedCrossRef
6.
go back to reference Di Pasquale G, Casella G. Antithrombotic strategies for atrial fibrillation: on the threshold of changes? Yes. J Thromb Haemost. 2005;3(3):428-432.PubMedCrossRef Di Pasquale G, Casella G. Antithrombotic strategies for atrial fibrillation: on the threshold of changes? Yes. J Thromb Haemost. 2005;3(3):428-432.PubMedCrossRef
7.
go back to reference Heidenreich PA, Solis P, Estes NAM, 3rd, et al. 2016 ACC/AHA clinical performance and quality measures for adults with atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2016;68(5):525-568.PubMedCrossRef Heidenreich PA, Solis P, Estes NAM, 3rd, et al. 2016 ACC/AHA clinical performance and quality measures for adults with atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2016;68(5):525-568.PubMedCrossRef
8.
go back to reference Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.PubMedCrossRef Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.PubMedCrossRef
9.
go back to reference Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5(2):e003074. Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5(2):e003074.
10.
go back to reference January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e151.PubMedCrossRef January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e151.PubMedCrossRef
11.
go back to reference Ozaki AF, Choi AS, Le QT, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2020;13(3):e005969.PubMedCrossRef Ozaki AF, Choi AS, Le QT, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2020;13(3):e005969.PubMedCrossRef
12.
go back to reference Hsu JC, Freeman JV. Underuse of vitamin K antagonist and direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: a contemporary review. Clin Pharmacol Ther. 2018;104(2):301-310.PubMedCrossRef Hsu JC, Freeman JV. Underuse of vitamin K antagonist and direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: a contemporary review. Clin Pharmacol Ther. 2018;104(2):301-310.PubMedCrossRef
13.
go back to reference Abdul-Rahim AH, Wong J, McAlpine C, Young C, Quinn TJ. Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation. Heart. 2014;100(7):557-562.PubMedCrossRef Abdul-Rahim AH, Wong J, McAlpine C, Young C, Quinn TJ. Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation. Heart. 2014;100(7):557-562.PubMedCrossRef
14.
go back to reference Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. Am J Med. 2014;127(11):1075-1082.e1071.PubMedCrossRef Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. Am J Med. 2014;127(11):1075-1082.e1071.PubMedCrossRef
15.
go back to reference Essien UR, Holmes DN, Jackson LR, 2nd, et al. Association of race/ethnicity with oral anticoagulant use in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiol. 2018;3(12):1174-1182.PubMedPubMedCentralCrossRef Essien UR, Holmes DN, Jackson LR, 2nd, et al. Association of race/ethnicity with oral anticoagulant use in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiol. 2018;3(12):1174-1182.PubMedPubMedCentralCrossRef
16.
go back to reference Essien UR, Magnani JW, Chen N, Gellad WF, Fine MJ, Hernandez I. Race/ethnicity and sex-related differences in direct oral anticoagulant initiation in newly diagnosed atrial fibrillation: a retrospective study of Medicare data. J Natl Med Assoc. 2020;112(1):103-108.PubMed Essien UR, Magnani JW, Chen N, Gellad WF, Fine MJ, Hernandez I. Race/ethnicity and sex-related differences in direct oral anticoagulant initiation in newly diagnosed atrial fibrillation: a retrospective study of Medicare data. J Natl Med Assoc. 2020;112(1):103-108.PubMed
17.
go back to reference Omole TD, Zhu J, Garrard W, et al. American Journal of Preventive Cardiology: Area Deprivation Index and oral anticoagulation in new onset atrial fibrillation. Am J Prev Cardiol. 2022;10:100346.PubMedPubMedCentralCrossRef Omole TD, Zhu J, Garrard W, et al. American Journal of Preventive Cardiology: Area Deprivation Index and oral anticoagulation in new onset atrial fibrillation. Am J Prev Cardiol. 2022;10:100346.PubMedPubMedCentralCrossRef
18.
go back to reference Nelson K, Taylor L, Lurie N, Escarce J, McFarland L, Fihn SD. Neighborhood environment and health status and mortality among veterans. J Gen Intern Med. 2011;26(8):862-867.PubMedPubMedCentralCrossRef Nelson K, Taylor L, Lurie N, Escarce J, McFarland L, Fihn SD. Neighborhood environment and health status and mortality among veterans. J Gen Intern Med. 2011;26(8):862-867.PubMedPubMedCentralCrossRef
19.
go back to reference Nelson K, Schwartz G, Hernandez S, Simonetti J, Curtis I, Fihn SD. The association between neighborhood environment and mortality: results from a national study of Veterans. J Gen Intern Med. 2017;32(4):416-422.PubMedCrossRef Nelson K, Schwartz G, Hernandez S, Simonetti J, Curtis I, Fihn SD. The association between neighborhood environment and mortality: results from a national study of Veterans. J Gen Intern Med. 2017;32(4):416-422.PubMedCrossRef
20.
go back to reference Rome BN, Gagne JJ, Avorn J, Kesselheim AS. Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: a population-based cohort study. Am Heart J. 2021;233:109-121.PubMedCrossRef Rome BN, Gagne JJ, Avorn J, Kesselheim AS. Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: a population-based cohort study. Am Heart J. 2021;233:109-121.PubMedCrossRef
21.
22.
23.
go back to reference Kind AJ, Jencks S, Brock J, et al. Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study. Ann Intern Med. 2014;161(11):765-774.PubMedPubMedCentralCrossRef Kind AJ, Jencks S, Brock J, et al. Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study. Ann Intern Med. 2014;161(11):765-774.PubMedPubMedCentralCrossRef
24.
go back to reference Gaffney A, Bor DH, Himmelstein DU, Woolhandler S, McCormick D. The effect of Veterans Health Administration coverage on cost-related medication nonadherence. Health Aff (Millwood). 2020;39(1):33-40.PubMedCrossRef Gaffney A, Bor DH, Himmelstein DU, Woolhandler S, McCormick D. The effect of Veterans Health Administration coverage on cost-related medication nonadherence. Health Aff (Millwood). 2020;39(1):33-40.PubMedCrossRef
25.
go back to reference Rose AJ, Goldberg R, McManus DD, et al. Anticoagulant prescribing for non-valvular atrial fibrillation in the Veterans Health Administration. J Am Heart Assoc. 2019;8(17):e012646.PubMedPubMedCentralCrossRef Rose AJ, Goldberg R, McManus DD, et al. Anticoagulant prescribing for non-valvular atrial fibrillation in the Veterans Health Administration. J Am Heart Assoc. 2019;8(17):e012646.PubMedPubMedCentralCrossRef
26.
go back to reference Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM. Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med. 2000;160(21):3252-3257.PubMedCrossRef Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM. Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med. 2000;160(21):3252-3257.PubMedCrossRef
27.
go back to reference Essien UR, Kim N, Magnani JW, et al. Association of race and ethnicity and anticoagulation in patients with atrial fibrillation dually enrolled in Veterans Health Administration and Medicare: effects of Medicare Part D on prescribing disparities. Circ Cardiovasc Qual Outcomes. 2022;15(2):e008389.PubMedCrossRef Essien UR, Kim N, Magnani JW, et al. Association of race and ethnicity and anticoagulation in patients with atrial fibrillation dually enrolled in Veterans Health Administration and Medicare: effects of Medicare Part D on prescribing disparities. Circ Cardiovasc Qual Outcomes. 2022;15(2):e008389.PubMedCrossRef
28.
go back to reference Essien UR, Kim N, Hausmann LRM, et al. Disparities in anticoagulant therapy initiation for incident atrial fibrillation by race/ethnicity among patients in the Veterans Health Administration System. JAMA Netw Open. 2021;4(7):e2114234.PubMedPubMedCentralCrossRef Essien UR, Kim N, Hausmann LRM, et al. Disparities in anticoagulant therapy initiation for incident atrial fibrillation by race/ethnicity among patients in the Veterans Health Administration System. JAMA Netw Open. 2021;4(7):e2114234.PubMedPubMedCentralCrossRef
29.
go back to reference Done N, Roy AM, Yuan Y, Pizer SD, Rose AJ, Prentice JC. Guideline-concordant initiation of oral anticoagulant therapy for stroke prevention in older veterans with atrial fibrillation eligible for Medicare Part D. Health Serv Res. 2019;54(1):128-138.PubMedCrossRef Done N, Roy AM, Yuan Y, Pizer SD, Rose AJ, Prentice JC. Guideline-concordant initiation of oral anticoagulant therapy for stroke prevention in older veterans with atrial fibrillation eligible for Medicare Part D. Health Serv Res. 2019;54(1):128-138.PubMedCrossRef
30.
go back to reference Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498.PubMedCrossRef Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498.PubMedCrossRef
31.
go back to reference Kilbourne AM, Switzer G, Hyman K, Crowley-Matoka M, Fine MJ. Advancing health disparities research within the health care system: a conceptual framework. Am J Public Health. 2006;96(12):2113-2121.PubMedPubMedCentralCrossRef Kilbourne AM, Switzer G, Hyman K, Crowley-Matoka M, Fine MJ. Advancing health disparities research within the health care system: a conceptual framework. Am J Public Health. 2006;96(12):2113-2121.PubMedPubMedCentralCrossRef
32.
go back to reference Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-272.PubMedCrossRef Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-272.PubMedCrossRef
33.
go back to reference Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.PubMedCrossRef Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.PubMedCrossRef
34.
go back to reference Orkaby AR, Nussbaum L, Ho YL, et al. The burden of frailty among U.S. veterans and its association with mortality, 2002-2012. J Gerontol A Biol Sci Med Sci. 2019;74(8):1257-1264.PubMedCrossRef Orkaby AR, Nussbaum L, Ho YL, et al. The burden of frailty among U.S. veterans and its association with mortality, 2002-2012. J Gerontol A Biol Sci Med Sci. 2019;74(8):1257-1264.PubMedCrossRef
35.
go back to reference January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104-132.PubMedCrossRef January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104-132.PubMedCrossRef
36.
go back to reference Essien UR, McCabe ME, Kershaw KN, et al. Association between neighborhood-level poverty and incident atrial fibrillation: a retrospective cohort study. J Gen Intern Med. 2022;37(6):1436-1443. Essien UR, McCabe ME, Kershaw KN, et al. Association between neighborhood-level poverty and incident atrial fibrillation: a retrospective cohort study. J Gen Intern Med. 2022;37(6):1436-1443.
37.
go back to reference LaRosa AR, Claxton J, O'Neal WT, et al. Association of household income and adverse outcomes in patients with atrial fibrillation. Heart. 2020;106(21):1679-1685.PubMedCrossRef LaRosa AR, Claxton J, O'Neal WT, et al. Association of household income and adverse outcomes in patients with atrial fibrillation. Heart. 2020;106(21):1679-1685.PubMedCrossRef
38.
go back to reference Johnson AE, Zhu J, Garrard W, et al. Area Deprivation Index and cardiac readmissions: evaluating risk-prediction in an electronic health record. J Am Heart Assoc. 2021;10(13):e020466.PubMedPubMedCentralCrossRef Johnson AE, Zhu J, Garrard W, et al. Area Deprivation Index and cardiac readmissions: evaluating risk-prediction in an electronic health record. J Am Heart Assoc. 2021;10(13):e020466.PubMedPubMedCentralCrossRef
39.
go back to reference Kargoli F, Shulman E, Aagaard P, et al. Socioeconomic status as a predictor of mortality in patients admitted with atrial fibrillation. Am J Cardiol. 2017;119(9):1378-1381.PubMedCrossRef Kargoli F, Shulman E, Aagaard P, et al. Socioeconomic status as a predictor of mortality in patients admitted with atrial fibrillation. Am J Cardiol. 2017;119(9):1378-1381.PubMedCrossRef
40.
go back to reference Rao SR, Reisman JI, Kressin NR, et al. Explaining racial disparities in anticoagulation control: results from a study of patients at the Veterans Administration. Am J Med Qual. 2015;30(3):214-222.PubMedCrossRef Rao SR, Reisman JI, Kressin NR, et al. Explaining racial disparities in anticoagulation control: results from a study of patients at the Veterans Administration. Am J Med Qual. 2015;30(3):214-222.PubMedCrossRef
41.
go back to reference Carlsson AC, Wandell P, Gasevic D, Sundquist J, Sundquist K. Neighborhood deprivation and warfarin, aspirin and statin prescription - a cohort study of men and women treated for atrial fibrillation in Swedish primary care. Int J Cardiol. 2015;187:547-552.PubMedPubMedCentralCrossRef Carlsson AC, Wandell P, Gasevic D, Sundquist J, Sundquist K. Neighborhood deprivation and warfarin, aspirin and statin prescription - a cohort study of men and women treated for atrial fibrillation in Swedish primary care. Int J Cardiol. 2015;187:547-552.PubMedPubMedCentralCrossRef
42.
go back to reference Zoller B, Li X, Sundquist J, Sundquist K. Neighbourhood deprivation and hospitalization for atrial fibrillation in Sweden. Europace. 2013;15(8):1119-1127.PubMedCrossRef Zoller B, Li X, Sundquist J, Sundquist K. Neighbourhood deprivation and hospitalization for atrial fibrillation in Sweden. Europace. 2013;15(8):1119-1127.PubMedCrossRef
43.
go back to reference Wandell P, Carlsson AC, Gasevic D, Sundquist J, Sundquist K. Neighbourhood socio-economic status and all-cause mortality in adults with atrial fibrillation: a cohort study of patients treated in primary care in Sweden. Int J Cardiol. 2016;202:776-781.PubMedCrossRef Wandell P, Carlsson AC, Gasevic D, Sundquist J, Sundquist K. Neighbourhood socio-economic status and all-cause mortality in adults with atrial fibrillation: a cohort study of patients treated in primary care in Sweden. Int J Cardiol. 2016;202:776-781.PubMedCrossRef
44.
go back to reference Affairs USDoV. Community Care Copayments. Published 2022. Accessed February 21, 2022. Affairs USDoV. Community Care Copayments. Published 2022. Accessed February 21, 2022.
45.
go back to reference Lunde ED, Joensen AM, Fonager K, et al. Socioeconomic inequality in oral anticoagulation therapy initiation in patients with atrial fibrillation with high risk of stroke: a register-based observational study. BMJ Open. 2021;11(5):e048839.PubMedPubMedCentralCrossRef Lunde ED, Joensen AM, Fonager K, et al. Socioeconomic inequality in oral anticoagulation therapy initiation in patients with atrial fibrillation with high risk of stroke: a register-based observational study. BMJ Open. 2021;11(5):e048839.PubMedPubMedCentralCrossRef
46.
go back to reference Sjolander M, Eriksson M, Asplund K, Norrving B, Glader EL. Socioeconomic inequalities in the prescription of oral anticoagulants in stroke patients with atrial fibrillation. Stroke. 2015;46(8):2220-2225.PubMedCrossRef Sjolander M, Eriksson M, Asplund K, Norrving B, Glader EL. Socioeconomic inequalities in the prescription of oral anticoagulants in stroke patients with atrial fibrillation. Stroke. 2015;46(8):2220-2225.PubMedCrossRef
47.
go back to reference Ohlsson H, Chaix B, Merlo J. Therapeutic traditions, patient socioeconomic characteristics and physicians’ early new drug prescribing--a multilevel analysis of rosuvastatin prescription in south Sweden. Eur J Clin Pharmacol. 2009;65(2):141-150.PubMedCrossRef Ohlsson H, Chaix B, Merlo J. Therapeutic traditions, patient socioeconomic characteristics and physicians’ early new drug prescribing--a multilevel analysis of rosuvastatin prescription in south Sweden. Eur J Clin Pharmacol. 2009;65(2):141-150.PubMedCrossRef
48.
go back to reference Barnes GD, Sippola E, Dorsch M, et al. Applying population health approaches to improve safe anticoagulant use in the outpatient setting: the DOAC Dashboard multi-cohort implementation evaluation study protocol. Implement Sci. 2020;15(1):83.PubMedPubMedCentralCrossRef Barnes GD, Sippola E, Dorsch M, et al. Applying population health approaches to improve safe anticoagulant use in the outpatient setting: the DOAC Dashboard multi-cohort implementation evaluation study protocol. Implement Sci. 2020;15(1):83.PubMedPubMedCentralCrossRef
49.
go back to reference Gutierrez JA, Christian RT, Aday AW, et al. Electronic alerts to initiate anticoagulation dialogue in patients with atrial fibrillation. Am Heart J. 2022;245:29-40.PubMedCrossRef Gutierrez JA, Christian RT, Aday AW, et al. Electronic alerts to initiate anticoagulation dialogue in patients with atrial fibrillation. Am Heart J. 2022;245:29-40.PubMedCrossRef
50.
go back to reference Essien UR, Dusetzina SB, Gellad WF. A policy prescription for reducing health disparities-achieving pharmacoequity. JAMA. 2021;326(18):1793-1794.PubMedCrossRef Essien UR, Dusetzina SB, Gellad WF. A policy prescription for reducing health disparities-achieving pharmacoequity. JAMA. 2021;326(18):1793-1794.PubMedCrossRef
Metadata
Title
Association of Neighborhood Disadvantage and Anticoagulation for Patients with Atrial Fibrillation in the Veterans Health Administration: the REACH-AF Study
Authors
Annie McDermott, BS
Nadejda Kim, MA
Leslie R.M. Hausmann, PhD, MS
Jared W. Magnani, MD, MSc
Chester B. Good, MD, MPH
Terrence M.A. Litam, MHA
Maria K. Mor, PhD
Toluwa D. Omole, BS
Walid F. Gellad, MD, MPH
Michael J. Fine, MD, MSc
Utibe R. Essien, MD, MPH
Publication date
23-09-2022
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 4/2023
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-022-07810-z

Other articles of this Issue 4/2023

Journal of General Internal Medicine 4/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine